Antimicrobial resistance pattern of Streptococcus agalactiae strains: five years evaluation of single center’

Aim: Streptococcus agalactiae is known to cause severe neonatal and postpartum infections. It also affects immunosuppressive patients. Penicillin is the first preferred antimicrobial agent in the treatment of these diseases. However, recent reports of penicillin tolerance and increased resistance to alternative antimicrobial agents in patients with penicillin allergies make treatment more difficult. In this study, we aimed to contribute to more effective treatment by determining antibiotic resistance profiles in GBS strains isolated from various clinical specimens. Material and Method: A total of 80 GBS strains isolated from various clinical specimens in clinical microbiology laboratory between 2012 and 2016 were evaluated retrospectively. Bacterial identification and antibiotic susceptibility tests were performed using conventional methods and an automated identification analyzer VITEK？-2 (BioMérieux, France). Results: All GBS isolates were found as susceptible to penicillin, imipenem, meropenem, linezolid, trimethoprim sulfamethoxazole, tigecycline, teicoplanin and vancomycin. The resistance rates of tetracycline, erythromycin, ciprofloxacin, clindamycin, moxifloxacin and ampicillin in isolates were 91.5%, 50.0%, 31.0%, 23.7%, 23.3% and 2.9% respectively. Conclusion: In our study, penicillin resistance was not observed in GBS isolates. Penicillin has been using as the first preferred agent in the treatment of these infections. However, considering the increasing resistance rates in alternative drugs, antimicrobial susceptibility testing for the effective treatment and prophylaxis of GBS infections is suggested